Skip Ribbon Commands
Skip to main content

Study Results

The CAVD’s Data & Materials Sharing Agreement states that the consortium whose members provided material used to generate the data from a standardized assay will then make reasonable efforts to disseminate such data to the broader scientific community. The following table provides links to the results from a number of studies conducted using standardized assays.

Click the "Public Study Title" to view the details of the study or click the "Study Overview and Results" to view the study results.

To search for a specific study, use the search box above the table.  Typical search logic using "OR" and "AND" is supported.  For example, Plasma OR Protein.

  
  
  
  
Development of a new class of immunogens for raising broadly neutralizing antibodies772Montefiori VIMCView Study Results
Potency Characterization of 3BNC117-LS-J and 10-1074-LS-J for Phase I Clinical Trial 723Montefiori VIMCView Study Results
Assessing the Immunogenicity of HIV-1 Env Vaccines Based on FP Prime/V2-SET Env Trimer Boost Regimen in a Guinea Pig Model694.01Montefiori VIMCView Study Results
Neutralizing activity against a Transmitted/Founder Envelope800Montefiori VIMCView Study Results
Neutralization breadth and potency of bNAbs and engineered bNAb reagents across large panels of HIV-1 strains746Montefiori VIMCView Study Results
Plasma depletion with heterologous envelope to identify bNAb epitopes779Montefiori VIMCView Study Results
Alum adsorbed 3M-052 adjuvant induces higher magnitude and strikingly durable (up to 1.5 years) autologous Tier-2 HIV-1 BG505 specific nAbs in rhesus macaques with sub-cutaneous and intramuscular routes of vaccination641Montefiori VIMCView Study Results
Characterization of MPER-specific antibodies elicited by MPER/liposome immunization in a mouse model666.01Montefiori VIMCView Study Results
Testing neutralization of monoclonal antibody (Lib95_4.2) for breadth788Montefiori VIMCView Study Results
Neutralizing activity of antibodies 1-18 and 2-12 against a 119-strain multiclade panel and a 100-strain clade C panel787Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals - NAb Assays584.05Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals - NAb Assays584.05Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-infected individuals584Montefiori VIMCView Study Results
Combination of HIV bNAbs delivered using Moderna’s mRNA-LNP technology can express functional antibodies with additive neutralization profiles568Montefiori VIMCView Study Results
E158 Mouse782Montefiori VIMCView Study Results
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells764Montefiori VIMCView Study Results
Nanoparticle PADRE 721775Montefiori VIMCView Study Results
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle790Montefiori VIMCView Study Results
Multi-Specific Antibodies and Variants-2 605.01Montefiori VIMCView Study Results
Antibody responses to BG505 SOSIP.664 with multiple adjuvants in a repeat dose intramuscular injection toxicity study in rats762Montefiori VIMCView Study Results
Inhibitory Breadth of D-peptide Entry Inhibitors736Montefiori VIMCView Study Results
IHV mAb screening767Montefiori VIMCView Study Results
IHV mAb screening - BAMA767.01Montefiori VIMCView Study Results
Sequential immunization strategies to elicit BNAbs in animals with a polyclonal B cell repertoire722Montefiori VIMCView Study Results
HIV-1 envelope vaccine: neglected sugar interactions may determine vaccine success386Montefiori VIMCView Study Results
Assessing the Immunogenicity of BG505 SET Scaffold Trimers in a Guinea Pig Model: HIV-1 Env Vaccin776Montefiori VIMCView Study Results
A comparison of the ADCC activity of mRNA-expressed PGT121 antibody to recombinant protein774.01Montefiori VIMCView Study Results
A comparison of the ADCP activity of mRNA-expressed PGT121 antibody to recombinant protein774Montefiori VIMCView Study Results
FLSC Phase I Clinical Trial - ADCC477.04Montefiori VIMCView Study Results
FLSC Phase I Clinical Trial - Fc Array477.03Montefiori VIMCView Study Results
FLSC Phase I Clinical Trial – ADCP assays and IgG glycan analyses477.02Montefiori VIMCView Study Results
FLSC Phase I Clinical Trial - Binding Ab Measurements and Linear Epitope Mapping via Peptide Microarra477.01Montefiori VIMCView Study Results
FLSC Phase I Clinical Trial – neutralizing antibody and ICS assays477Montefiori VIMC, Koup VIMCView Study Results
HIV BG505 SOSIP.664 protein formulated with adjuvants in guinea pigs - Binding Ab assays708.01Montefiori VIMCView Study Results
Immunogenicity of BG505 SOSIP.664 with adjuvants in guinea pigs 708Montefiori VIMCView Study Results
Relative ADCP activity as a correlate of risk in an adenoviral vector prime VLP boost vaccine regimen465.02Montefiori VIMCView Study Results
EV06656Montefiori VIMCView Study Results
Optimization of HIV bNAbs537Montefiori VIMCView Study Results
Optimization PGDM1400 PK720Montefiori VIMCView Study Results
Challenge virus-specific T helper cell responses induced by adenoviral vector prime VLP booster immunization regimens do not correlate with enhanced susceptibility to virus acquisition465Montefiori VIMC, Koup VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals - 3BNC117 PK via ELISA584.01Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals – 10-1074 PK via ELISA584.02Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals - 3BNC117 ADA584.03Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-positive individuals – 10-1074 ADA584.04Montefiori VIMCView Study Results
Ancillary ADA Assessment: A phase 1 study of the safety, PK and antiretroviral activity of 3BNC117mAb in humans446.01Montefiori VIMCView Study Results
17-12 Ad26 Env Adjuvant Study703Montefiori VIMCView Study Results
Fv and Fc characterization of the 17-12 Ad26 Env Adjuvant Study703.01Montefiori VIMCView Study Results
Functional characterization of the 17-12 Ad26 Env Adjuvant Study703.02Montefiori VIMCView Study Results
ADA measurement for MCA-885 (10-1074 in HIV-infected and HIV-uninfected individuals)514.02Montefiori VIMCView Study Results
A comparison of the protein vaccine A244 gp120 D11 and the mRNA-expressed vaccine, and an examination of different boosting regimens for the mRNA vaccine.745Montefiori VIMCView Study Results
A comparison of the protein vaccine A244 gp120 D11 and the mRNA-expressed vaccine, and an examination of different boosting regimens for the mRNA vaccine.745.01Montefiori VIMCView Study Results
Immunogenicity of a Novel, Stable BG505 Env Immunogen Incorporating a Soluble Trans-Membrane Domain versus BG505 SOSIP and Fold-on Envs in Guinea Pigs 695Montefiori VIMCView Study Results
Characterization of antibodies obtained in the Pantaleo 662/662.01 Env Rabbit Studies662Montefiori VIMCView Study Results
Characterization of antibodies obtained in the Pantaleo 662/662.01 Env Rabbit Studies662.01Montefiori VIMCView Study Results
Immunogenicity of BG505 SOSIP.664 with adjuvants in rats724Montefiori VIMCView Study Results
Immunogenicity of BG505 SOSIP.664 with adjuvants in rats724.01Montefiori VIMCView Study Results
A two-component self-assembling protein nanoparticle system that presents twenty native-like HIV-1 Env trimers706Montefiori VIMCView Study Results
Closing and opening holes in the glycan shield of HIV-1 B41 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to newly unmasked epitopes648Montefiori VIMCView Study Results
Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers647Montefiori VIMCView Study Results
Closing and opening holes in the glycan shield of HIV-1 BG505 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to newly unmasked epitopes646Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-negative individuals - 3BNC117 ADA583.03Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-negative individuals - 10-1074 ADA583.04Montefiori VIMCView Study Results
PK analysis of optimized PGT121-LS variants in human FcRn knock-in mice719Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-negative individuals583Montefiori VIMCView Study Results
3BNC117 plus 10-1074 in HIV-negative individuals - 3BNC117 PK via ELISA583.01Montefiori VIMCExploratory Results
3BNC117 plus 10-1074 in HIV-negative individuals - 10-1074 PK via ELISA583.02Montefiori VIMCExploratory Results
Neutralization Assays in RV305_079 Supernatants 570Montefiori VIMCView Study Results
Discovery of improved bNAbs for HIV-1 immunotherapy and prevention642Montefiori VIMCView Study Results
Characterization of 10-1074 escape mutations in humans following 10-1074 infusion514.01Montefiori VIMCView Study Results
Mouse Immunogenicity Study using CD4-independent Envelopes [CD4i 89.6 (A2) and CD4i 89.6N7 (D4T)]462Montefiori VIMCView Study Results
Evaluation of the neutralizing activity of Fc-modified and bispecific bNAbs569Montefiori VIMCView Study Results
NHP Immunogenicity Study of CD4i Env (MX2)463Montefiori VIMC, Koup VIMCView Study Results
Screening for bNabs derived from plasma489Montefiori VIMCView Study Results
Plasma Neut Assay on RV328 #328039631.01Montefiori VIMCView Study Results
Neutralization Potency of 10E8-like bnAbs645Montefiori VIMCView Study Results
Antibody-dependent cellular cytotoxicity (ADCC) activity in SOSIP immunized rabbits677Montefiori VIMCView Study Results
Immunogenicity of HIV Vaccine Designs Incorporating Neutralizing Antibody Signatures694Montefiori VIMCView Study Results
HIV-1 mAb screening 2489.01Montefiori VIMCView Study Results
HIV-1 mAb screening 2489.01Montefiori VIMCView Study Results
Plasma depletion with autologous envelope to identify bNAb epitopes615.02Montefiori VIMCView Study Results
Neutralization breadth in the context of murine autoimmunity707Montefiori VIMCView Study Results
Env antibody responses to adenoviral vector prime - VLP boost immunization regimens465.01Montefiori VIMCView Study Results
Sequential immunization in wild type mice494.03Montefiori VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy 563.05Koup VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy 563.01Montefiori VIMCView Study Results
Non-human primate challenge study comparing vesicular stomatitis virus (VSV) vectors transiently and stably expressing the VSV G glycoprotein548.03Montefiori VIMCView Study Results
Nonhuman primate challenge study comparing vesicular stomatitis virus (VSV) vectors transiently and stably expressing the VSV G glycoprotein548.02Montefiori VIMCView Study Results
Serum neutralization responses in rabbits to BG505 SOSIP.664 gp140, with or without GSK’s AS01B adjuvant.681.01Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633.02)633.02Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623.01)623.01Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623.02)623.02Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623)623Montefiori VIMCView Study Results
Characterization of MPER specific antibodies elicited by MPER/liposome immunization in a mouse model666Montefiori VIMCView Study Results
1.1.2 antibody neuts – Unique ID 572572Montefiori VIMCView Study Results
1.1.2 antibody neuts – Unique ID 572572Montefiori VIMCView Study Results
Screening for bNAbs in HIV infected Patients474.01Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633.01)633.01Montefiori VIMCView Study Results
Plasma depletion to identify bNAb epitopes615.01Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633)633Montefiori VIMCView Study Results
Screening for bNAbs in HIV infected Patients474.01Montefiori VIMCView Study Results
1 - 100Next